![]() ![]() ![]() Patients with any other significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which may interfere with the completion of the study. ![]() octreotide long-acting), which cannot be interrupted for at least 6 weeks before the administration of Lutathera. Any patient receiving treatment with short-acting octreotide, which cannot be interrupted for 24 h before and 24 h after the administration of Lutathera, or any patient receiving treatment with SSAs (e.g.Hyperkaleamia > 6.0 mmol/L (CTCAE Grade 3) which is not corrected prior to study enrolment.Uncontrolled diabetes mellitus as defined by hemoglobin A1c value > 7.5%.Serum albumin 470 msec for females and QTcF > 450 msec for males or congenital long QT syndrome.Patients who have provided a signed informed consent form to participate in the study, obtained prior to the start of any protocol related activities.Presence of at least 1 measurable site of disease.The tumor uptake observed in the target lesions must be > normal liver uptake.NETSPOT®), Somatostatin Receptor scintigraphy (SRS) with -pentetreotide (Octreoscan® SPECT/CT), SRS with -Tektrotyd, -DOTA-TATE PET/CT (or MRI when applicable based on target lesions) imaging. Somakit-TOC®) PET/CT (or MRI when applicable based on target lesions) imaging, -DOTA-TATE PET/CT (or MRI when applicable based on target lesions) imaging (e.g. Expression of somatostatin receptors on all target lesions documented by CT/MRI scans, assessed by any of the following somatostatin receptor imaging (SRI) modalities within 3 months prior to randomization: -DOTA-TOC (e.g.Patients ≥ 15 years of age and a body weight of > 40 kg at screening.Presence of metastasized or locally advanced, inoperable (curative intent) histologically proven, well differentiated Grade 2 or Grade 3 gastroenteropancreatic neuroendocrine (GEP-NET) tumor diagnosed within 6 months prior to screening.Why Should I Register and Submit Results?. ![]()
0 Comments
Leave a Reply. |